First-in-Country TomoTherapy® Systems Operate in Thailand and the Philippines

TomoTherapy System Provides Patients Accurate and High Quality Individualized Treatments

SUNNYVALE, Calif., May 24, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that Maharaj Nakorn Chiang Mai Hospital (‘Chiangmai University Hospital’) in Chiang Mai, Thailand and Makati Medical  Center (‘MakatiMed’) in Manila, Philippines have begun treating patients with the TomoTherapy® System, a fully-integrated, 3D image-guided intensity modulated radiation therapy (IG-IMRT).  The TomoTherapy System allows Chiangmai University Hospital and MakatiMed to offer patients a non-invasive, personalized option for the treatment of tumors throughout the body, making these two hospitals the first-in-country installed sites of the TomoTherapy System in the ASEAN region. Both hospitals commenced treatment of their first patients in the spring.

“Being one of the most reputable hospitals and the first hospital with TomoTherapy Hi·Art System available in Northern Thailand, we are committed to providing patients the best technological innovations for cancer care and the highest quality of healthcare services,” said Dr. Somsak, Wanwilairat, Ph. D, Chief Physicist, Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai University. “We recognize that the IMRT for treating a wide range of cancers is a viable option to meet the needs of a diverse patient population across 17 provinces in the northern region and foreign patients with shortened room treatment time.”

 “TomoTherapy perfectly combines image-guided technology and radiation treatment delivery capabilities. We can address almost all types of cancers, from irregularly shaped tumors to long treatment fields like multiple tumors along the spine or in the brain,” said Dr. Kathleen Baldivia, head of MakatiMed’s Radiation Oncology Section. “With the radiation beam further subdivided into beamlets, TomoTherapy allows doctors to give varying doses across one treatment area, thus resulting in reduced toxicity and improving patients’ quality of life.”

The TomoTherapy System combines a revolutionary design, with industry-leading treatment precision and daily image guidance for true treatment accuracy. The TomoTherapy System is a fully-integrated, 3D image-guided intensity modulated radiation therapy (IG-IMRT) system. Through daily CT imaging, the TomoTherapy System allows clinicians to give each patient accurate and high quality individualized treatments specifically tailored to their needs. Unique helical delivery means a broader range of tumors can be treated, expanding options for more patients.

“We are pleased to extend the benefits of TomoTherapy treatment and daily image guidance to patients in Thailand, The Philippines and surrounding regions,” said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. “As leading hospitals in the ASEAN region Chiangmai University Hospital’s and MakatiMed’s installations mark a significant milestone for Accuray as we look forward to expanding our global presence and improving access to treatment solutions that improve patient outcomes and care.”

About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

 

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to reputation, the anticipated benefits of the TomoTherapy System, quality of care, the expansion of our global presence, and the Company’s leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the Company’s reports Form 10-Q for the first, second and third quarters of fiscal 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.  Accordingly, investors should not place undue reliance on any forward-looking statements.

# # #